Analysts Anticipate X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) to Announce -$0.68 Earnings Per Share

Wall Street brokerages expect that X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) will post ($0.68) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for X4 Pharmaceuticals’ earnings. The highest EPS estimate is ($0.47) and the lowest is ($0.82). X4 Pharmaceuticals posted earnings of ($0.91) per share during the same quarter last year, which indicates a positive year over year growth rate of 25.3%. The business is scheduled to report its next quarterly earnings report on Thursday, March 3rd.

According to Zacks, analysts expect that X4 Pharmaceuticals will report full-year earnings of ($3.06) per share for the current fiscal year, with EPS estimates ranging from ($3.42) to ($2.79). For the next financial year, analysts expect that the firm will post earnings of ($2.78) per share, with EPS estimates ranging from ($3.93) to ($2.34). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for X4 Pharmaceuticals.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings data on Thursday, November 4th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.04). During the same quarter last year, the firm posted ($0.87) EPS.

A number of research firms recently weighed in on XFOR. HC Wainwright reduced their price objective on shares of X4 Pharmaceuticals from $21.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, December 14th. Zacks Investment Research lowered shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 8th.

A number of large investors have recently made changes to their positions in the business. LMR Partners LLP bought a new stake in shares of X4 Pharmaceuticals during the 2nd quarter worth $66,000. Morgan Stanley lifted its holdings in shares of X4 Pharmaceuticals by 227.8% during the 2nd quarter. Morgan Stanley now owns 10,242 shares of the company’s stock worth $67,000 after acquiring an additional 7,118 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of X4 Pharmaceuticals during the 2nd quarter worth $85,000. Marshall Wace LLP bought a new stake in shares of X4 Pharmaceuticals during the 2nd quarter worth $89,000. Finally, Alpine Global Management LLC bought a new stake in shares of X4 Pharmaceuticals during the 2nd quarter worth $110,000. 71.55% of the stock is owned by hedge funds and other institutional investors.

X4 Pharmaceuticals stock traded down $0.08 during mid-day trading on Friday, reaching $2.09. The company’s stock had a trading volume of 205,335 shares, compared to its average volume of 240,609. X4 Pharmaceuticals has a 12-month low of $1.80 and a 12-month high of $10.70. The company has a market capitalization of $51.64 million, a P/E ratio of -0.56 and a beta of 0.33. The company has a debt-to-equity ratio of 0.48, a quick ratio of 6.10 and a current ratio of 6.10. The firm’s fifty day moving average price is $3.35 and its two-hundred day moving average price is $4.69.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003.

Further Reading: FAANG Stocks

Get a free copy of the Zacks research report on X4 Pharmaceuticals (XFOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.